|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The [<sup>99m</sup>Tc]Tc-NOTA-sst<sub>2</sub>-ANT complex demonstrated high tumor uptake and rapid clearance in a SSTR-tumor mouse model, showing potential for further development.
|
31129499 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Here we determine the effect of the tumor suppressor protein, p53, on trafficking (64)Cu to tumor cell nuclei from DOTA vs. CB-TE2A-conjugated agonist Y3-TATE and the antagonist (64)Cu-CB-TE2A-sst2-ANT in cell lines that are positive or negative for p53.
|
22056254 |
2012 |
|
Bone Marrow Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, the ANT group had worse myelopathy scores (mJOAS<sub>ANT group</sub> = 13.5 ± 2.5, mJOAS<sub>A/P group</sub> = 15.7 ± 2.2).
|
29916066 |
2019 |
|
Spinal Cord Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, the ANT group had worse myelopathy scores (mJOAS<sub>ANT group</sub> = 13.5 ± 2.5, mJOAS<sub>A/P group</sub> = 15.7 ± 2.2).
|
29916066 |
2019 |
|
Hypothalamic hamartomas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ABBREVIATIONS AED = antiepileptic drug; ANT = anterior nucleus of the thalamus; BOLD = blood oxygen level dependent; CCEP = cortico-cortical evoked potential; DBS = deep brain stimulation; ECoG = electrocorticography; ERSET = Early Randomized Surgical Epilepsy Trial; FCD = focal cortical dysplasia; HH = hypothalamic hamartoma; LITT = laser interstitial thermal therapy; RCT = randomized controlled trial; r-fMRI = resting-state functional MRI; RNS = responsive neurostimulation; SEEG = stereo-electroencephalography; VNS = vagus nerve stimulation.
|
30970205 |
2019 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
Biomarker
|
disease |
BEFREE |
One clinical isolate (BE/ANT-A11/17) replicated very efficiently in all cell lines, and remarkably, even better than RSV A2 in the HEp-2 cell line.
|
31698728 |
2019 |
|
Drug Resistant Epilepsy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This is the first study in which favorable outcomes of ANT-DBS surgery were observed in individual patients with refractory epilepsy who had not responded to prior VNS.
|
31533117 |
2019 |
|
Aphasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The primary outcome measures for changes in language performance were the Western Aphasia Battery's aphasia quotient AQ; the secondary outcome measures were the Boston naming test (BNT) and the Action naming test (Action BNT, ANT).All subjects completed the study.
|
30778280 |
2018 |
|
Cardiac Arrest
|
0.010 |
Biomarker
|
disease |
BEFREE |
SCA type 6 showed lower metabolic ratios in almost all cerebellar subregions (ANT, 0.57 ± 0.06, p < 0.001) except INFV.
|
28319124 |
2017 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
This study demonstrated that ANT-DBS can reduce seizure frequency in the early stage in epileptic rats as well as relieve the pro-inflammatory state and neuronal injury, which may be one of the most effective mechanisms of ANT-DBS against epileptogenesis.
|
28027874 |
2017 |
|
Neuroendocrine Tumors
|
0.010 |
Biomarker
|
group |
BEFREE |
A somatostatin receptor (SSTR)-targeting antagonist peptide (sst<sub>2</sub>-ANT) was radiolabeled with <sup>99m</sup>Tc tricarbonyl via a tridentate [N,S,N]-type ligand (L) to develop a radiodiagnostic agent, <sup>99m</sup>TcL-sst<sub>2</sub>-ANT, for imaging of SSTR-expressing neuroendocrine tumors.
|
28043006 |
2017 |
|
Bipolar Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There were no differences between the two at-risk groups (i.e., youth with BD parent vs. youth with MDD parent) on any ANT-S measure.
|
22980403 |
2013 |
|
Refractory cancer
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, the AME genes involved in aminoglycoside-clinical resistance were aac(3)-IIa, aac(6')-Ib, and ant(2″)-Ia, genes that confer resistance to tobramycin, gentamicin, and amikacin.
|
23206280 |
2013 |
|
Major Depressive Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There were no differences between the two at-risk groups (i.e., youth with BD parent vs. youth with MDD parent) on any ANT-S measure.
|
22980403 |
2013 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Also, miRNA expression profiles of the BC and their corresponding ANT were evaluated.
|
22524830 |
2012 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Also, miRNA expression profiles of the BC and their corresponding ANT were evaluated.
|
22524830 |
2012 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Unlike the ANT1 and ANT3 isoforms, ANT2 is not pro-apoptotic and may therefore contribute to carcinogenesis.
|
20950584 |
2011 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The altered isoform expression in DCM hearts entails changes in the kinetic properties of total ANT protein restricting ANT function and contributing to disturbed energy metabolism in DCM.
|
16107323 |
2006 |
|
Enterovirus Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
An enteroviral infection is linked to changes in the ANT isoform expression in human heart tissue, which shows little or no evidence of an active T-cell dependent immune response.
|
10841224 |
2000 |
|
Mitochondrial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
These results indicate that ANT has a role in mtDNA maintenance and that a mitochondrial disease can be caused by a dominant mechanism.
|
10926541 |
2000 |